iABC

October 31, 2019October 31, 2019

Alaxia Joins iABC Consortium to Accelerate Development of ALX-009, Its Lead Antimicrobial Agent

News

Alaxia has joined the inhaled Antibiotics in Bronchiectasis and Cystic Fibrosis (iABC) consortium as a partner in a collaborative project that seeks to accelerate the development of two inhaled antimicrobial ... Read more

June 27, 2019June 27, 2019

Preclinical Data Supports Development of Inhaled Form of Murepavadin to Fight P. Aeruginosa Infections

News

A new experimental antibiotic named murepavadin is both safe and effective at fighting bacterial lung infections caused by Pseudomonas aeruginosa when given via inhalation, a study in mice shows. These ... Read more

October 17, 2017October 17, 2017

Polyphor Launches Development of Inhaled Antibiotic for Respiratory Diseases

News

Polyphor, a Swiss specialty pharmaceutical company, is launching the development of an inhaled form of the investigational antibiotic murepavadin (POL7080). Murepavadin, a type of outer membrane protein targeting antibiotic (OMPTA), ... Read more